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Abstract 
The rapid diagnosis of carbapenemase-producing (CP) bacteria is essential for the management of 
therapy and infection control. In this study, RAPIDEC® CARBA NP (RCNP) was evaluated for the 
rapid screening of CP Enterobacteriaceae, Acinetobacter baumannii complex and Pseudomonas 
aeruginosa from clinical specimens collected at five Italian hospitals. Firstly, each site tested 20 
well-characterized strains in a blinded fashion. Secondly, each center prospectively tested 25 
isolates from blood cultures processed with a rapid workflow (6 hours after subculture) and 25 
isolates from other specimens processed after an overnight culture. The presence of carbapenemases 
was confirmed by multiplex Real-Time-PCRs targeting carbapenemase genes. RCNP presented an 
overall sensitivity, specificity, positive predictive value, and negative predictive value of 70%, 94%, 
82%, and 89%, respectively, with a higher performance in detection of CP Enterobacteriaceae and 
a poorer performance in detection of CP A. baumannii complex. With isolates from blood cultures, 
RCNP could significantly reduce the time required for identification of CP Enterobacteriaceae (less 
than 9 hours since the positivization of blood cultures). 
 
1. Introduction 
Antibiotic resistance is an issue of growing importance for public health, and involves a large 
variety of pathogenic bacteria responsible for healthcare-associated and community-acquired 
infections (Tang et al., 2014). Carbapenems are considered among the last resort antibiotics for 
treatment of resistant Gram-negatives (Papp-Wallace et al., 2011), but carbapenem-resistant strains 
of Enterobacteriaceae and Gram-negative nonfermenters are now spreading worldwide (Ruppé et 
al., 2015). The main mechanisms of resistance to carbapenems in Gram-negative pathogens are 
represented by the production of carbapenemases, reduction of outer membrane permeability 
mediated by the loss of porin function, and upregulation of efflux systems (Papp-Wallace et al., 
2011). The spread of carbapenemase-producing (CP) strains of Gram-negative bacteria (GNB), 
including Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp., is of notable 
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concern since these strains often carry additional resistance determinants and exhibit complex 
multidrug-resistant (MDR) phenotypes. Moreover, carbapenemase genes are usually associated with 
mobile genetic elements and their expression can be associated with higher-level carbapenem 
resistance (Kaye and Pogue, 2015; Rossolini et al., 2014; Ruppé et al., 2015). 
Therefore, rapid identification of CP-GNB is important to implement infection control strategies 
that limit their spread in hospitals, and to the selection of appropriate antimicrobial therapy 
(Miriagou et al., 2010). Several approaches can be used for rapid identification of CP-GNB, 
including phenotypic and genotypic methods (Osei et al, 2015). Among the phenotypic methods, 
the RAPIDEC® CARBA NP test (bioMérieux, Marcy l’Etoile, France) is a commercial test for rapid 
screening of CP-GNB developed basing on the original CARBA NP colorimetric method 
(Nordmann et al., 2012). The RAPIDEC® CARBA NP test is easy to use and provides results in two 
hours, while being cheaper than molecular assays and able to detect also unknown carbapenemase 
genes. This test, based on the colorimetric detection of hydrolysis of imipenem using phenol red as 
indicator, has been previously validated or compared with other tests in several studies in which it 
was retrospectively applied on a collection of isolates previously characterized for the presence of 
carbapenemases (Poirel and Nordmann, 2015; Dortet et al., 2015; Hombach et al., 2015; Garg et al., 
2015; Lifshitz et al., 2016; Kabir et al., 2016; Österblad et al., 2016; Aktaş et al., 2016), or 
prospectively applied on Enterobacteriaceae isolates (Noël et al., 2016). 
In this work, we carried out a multicenter evaluation of the RAPIDEC® CARBA NP test, including 
a proficiency test with well-characterized strains, followed by further testing for the detection of 
CP-GNB among bacterial isolates prospectively collected from various clinical specimens. 
Moreover, a fast-track workflow for the detection of CP-GNB using the RAPIDEC® CARBA NP 
from blood cultures was implemented. 
 
2. Materials and methods 
2.1 Participating centers 
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Five laboratories associated with hospitals located in northern (Lecco and Modena) and central 
(Florence and Rome) Italy, representative of different Italian Regions, were involved in the study 
carried out from April to September 2015. 
2.2 Proficiency test 
A collection of 20 well-characterized strains, previously confirmed as CP (n=14) or carbapenem-
resistant but carbapenemase-non-producers (CNP, n=4) or carbapenem-susceptible (n=2) (Table 1), 
was provided to each participating center in a blinded fashion. Each strain was cultured for 18-24 
hours on blood agar and then tested with the RAPIDEC® CARBA NP test according to the 
Manufacturer’s instructions. 
2.3 Test on clinical isolates 
A total of 250 (50 per participating center) consecutive, non-replicate clinical isolates of 
Enterobacteriaceae and Gram-negative nonfermenters (P. aeruginosa and A. baumannii complex) 
were tested with RAPIDEC® CARBA NP. Of them, 125 isolates (25 per participating center) were 
from blood cultures processed with a fast-track workflow, and 125 isolates (25 per participating 
center) were from other clinical specimens (surveillance specimens were not included). Positive 
blood cultures from BACTEC™ (Becton Dickinson, Franklin Lakes, NJ, USA) or BacT/ALERT® 
(bioMérieux) systems were evaluated with Gram staining and plated onto blood agar plates 
(bioMérieux). The fast-track workflow foresaw that after six hours of incubation (35±2°C, 5% 
CO2), bacterial isolates were identified by MALDI-TOF with the VITEK® MS system (bioMérieux) 
and, if they belonged to the target species, they were included in the study and tested with the 
RAPIDEC® CARBA NP test. Since the laboratories did not process positive blood cultures on a 
24/7 schedule, only the blood cultures that became positive during the night or in the morning (until 
12 a.m.) were processed with the fast-track workflow, by the staff in charge of the afternoon shift. 
Blood cultures yielding Gram-positive bacteria or mixed Gram-positive/Gram-negative bacteria 
and/or yeasts at Gram staining were excluded (Figure 1). Urine samples were cultured on chromID® 
CPS® Elite medium (bioMérieux) for 18-24 hours, while other materials were cultured on blood 
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agar (bioMérieux) for 18-24 hours. Bacterial isolates were identified by MALDI-TOF with the 
VITEK® MS system (bioMérieux) and, if they belonged to the target species, they were included in 
the study and tested with the RAPIDEC® CARBA NP (Figure 1).  
2.4 RAPIDEC® CARBA NP test 
The RAPIDEC® CARBA NP test was performed according to the Manufacturer's instructions, as 
follows. In case of isolated colonies from 18-24 hour-old cultures, several colonies were deposited 
in the dedicated well. For the 6-hour bacterial growth from blood cultures, the bacterial growth was 
transferred directly to the well of RAPIDEC® CARBA NP, until the indicated turbidity was reached. 
Samples presenting an insufficient bacterial growth were excluded. Strips were incubated at 
35±2 °C for up to 120 minutes, and inspected at 30, 60 and 120 minutes. Results were interpreted 
by comparing the test well and the control well colors. A test was considered positive when a 
change of color of the well (from red to red-orange, orange or yellow) was observed. 
2.5 Antimicrobial susceptibility testing  
Antimicrobial susceptibility testing (AST) was performed using reference broth microdilution 
according to CLSI guidelines (CLSI, 2015) and results were interpreted according to EUCAST 
criteria v 6.0 (http://www.eucast.org/clinical_breakpoints/). 
2.6 Molecular detection of carbapenemase genes  
After performing the RAPIDEC® CARBA NP, each isolate was processed with three homebrew 
multiplex Real-Time-PCR mixes for the detection of the main carbapenemase genes, including 
blaKPC, blaVIM, blaNDM, blaOXA-48-like genes in Enterobacteriaceae, blaIMP, blaVIM, blaFIM-1, blaGES 
genes in P. aeruginosa, and blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, ISAba1+blaOXA-51-like genes for 
A. baumannii complex. Primers and probes used in every reaction, and reaction conditions are 
described in Table 2. An internal control, consisting of phocine herpesvirus DNA (PhHV), and 
primers and probe targeting PhHV, was added in each reaction mix as a positive amplification 
control (Van Doornum et al., 2003).  
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2.7 Spectrophotometric assay 
All meropenem non-susceptible isolates which tested negative with molecular assays for the 
detection of carbapenemase genes were further investigated by a spectrophotometric assay with 
crude extracts, using imipenem as substrate, as previously described (Lauretti et al., 1999), for 
detection of carbapenemase activity to exclude the presence of carbapenemase types not included in 
the molecular assay. 
 
3. Results 
3.1 Proficiency test with RAPIDEC® CARBA NP 
Considering that RAPIDEC® CARBA NP is based on a colorimetric method and results are 
assigned by visual inspection, a proficiency test was initially performed with a collection of 20 
well-characterized strains provided to each participating center in a blinded fashion, to evaluate the 
reproducibility of interpretation of results obtained at different centers.  
All the CNP (n=4) and the susceptible (n=2) strains were correctly identified as carbapenemase-
negative with the RAPIDEC® CARBA NP test by all laboratories, while four of the 14 CP strains 
were not reported as carbapenemase-positive by one or more laboratories. In particular, the OXA-
58-positive A. baumannii complex strain was not detected as CP by two laboratories, while the 
FIM-1-positive and the IMP-13-positive P. aeruginosa strains, and the OXA-372-positive 
Citrobacter freundii strain, were not detected as CP by one laboratory each (Table 1). 
The overall good results of the proficiency test (specificity for detection of CP, 100%; sensitivity for 
detection of CP, 93%) prompted us to proceed with the analysis of isolates from clinical samples in 
each center. 
3.2 Performance of the RAPIDEC® CARBA NP test on isolates from clinical specimens other than 
blood cultures 
Among 125 isolates from various materials (mainly urine and respiratory specimens), 31 were 
confirmed as CP by molecular methods. These isolates included 10 KPC-producing K. pneumoniae, 
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one OXA-48-producing K. pneumoniae, one KPC- and VIM-coproducing K. pneumoniae, and 19 
class D carbapenemase-producing A. baumannii complex (n=16 OXA-23-like, n=2 OXA-24-like, 
n=1 OXA-51-like overexpressed by an ISAba1 inserted upstream). Of these, the RAPIDEC® 
CARBA NP test correctly detected the 12 CP Enterobacteriaceae, but failed to identify 11 of the 19 
CP A. baumannii complex (including 9 positive for a blaOXA-23-like gene, one positive for a blaOXA-24-
like gene, and one carrying a blaOXA-51-like gene preceded by an ISAba1 insertion sequence). 
Moreover, the RAPIDEC® CARBA NP test was positive with one K. pneumoniae and five P. 
aeruginosa for which the molecular tests and the spectrophotometric assay had not identified 
carbapenemases (Table 3). Consequently, overall sensitivity, specificity, positive predictive values 
(PPV), and negative predictive values (NPP) were found to be 65%, 94%, 77%, and 89%, 
respectively. If A. baumannii complex strains were not included in the study, the sensitivity, 
specificity, PPV and NPP of RAPIDEC® CARBA NP would be 100%, 93%, 67%, 100%, 
respectively. Considering only the 61 Enterobacteriaceae isolates, the test yielded an even better 
performance (100%, 98%, 92%, 100%, respectively) (Table 4). 
3.3 Performance of the RAPIDEC® CARBA NP test with positive blood cultures in a fast-track 
workflow 
Of the 125 isolates from blood cultures tested with RAPIDEC® CARBA NP, 122 gave interpretable 
results, while three isolates (one P. aeruginosa, one A. baumannii complex and one Enterobacter 
cloacae) yielded insufficient growth to perform the test at 6 hours after subculture. Among the 122 
evaluable isolates, 36 were confirmed as CP by molecular methods, including 18 KPC-producing K. 
pneumoniae, two OXA-48-producing K. pneumoniae, one VIM-producing K. pneumoniae, three 
VIM-producing P. aeruginosa and 12 class D carbapenemase-producing A. baumannii complex 
(n=10, OXA-23-like; n=1, OXA-24-like; n=1, OXA-23-like and OXA-24-like co-producer). Of 
them, RAPIDEC® CARBA NP assay correctly identified 27 isolates as CP, but missed nine A. 
baumannii complex carrying blaOXA-23-like and/or blaOXA-24-like genes (Table 3). RAPIDEC® CARBA 
NP correctly categorized as CNP 82 out of 86 isolates from blood cultures, while false-positive 
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results were obtained with one K. pneumoniae and three P. aeruginosa isolates for which no 
carbapenemase genes nor carbapenemase activity were detected using Real-Time-PCRs and 
spectrophotometric activity, respectively. According to these results, the RAPIDEC® CARBA NP 
showed a sensitivity of 75%, a specificity of 95%, a PPV of 87%, and a NPV of 90%. However, 
excluding the A. baumannii complex isolates, sensitivity, specificity, PPV and NPV were 100%, 
95%, 86%, 100%, respectively, and these percentages further increased when considering only the 
81 Enterobacteriaceae isolates (100%, 98%, 95%, 100%, respectively) (Table 4). 
3.4 Overall performance of the RAPIDEC® CARBA NP test with clinical isolates 
Overall, considering all types of clinical specimens, the RAPIDEC® CARBA NP test yielded 
sensitivity, specificity, PPV and NPP of 70%, 94%, 82%, and 89%, respectively. The best results 
were observed with Enterobacteriaceae, as described in Table 4.  
No significant differences were observed among the performance of the RAPIDEC® CARBA NP 
test carried out at the five centers. 
 
4. Discussion 
The global spread of CP-GNB represents a major public health challenge. Clinical Microbiology 
laboratories are increasingly asked for rapid detection of CP strains for infection control and 
antimicrobial stewardship purposes. 
The RAPIDEC® CARBA NP test is a simple phenotypic test that does not require any specific 
technical skills or expensive equipment (Poirel and Nordmann, 2015; Garg et al., 2015), which 
allows rapid detection of CP strains in a timeframe comparable to that of molecular tests (i. e. 1-2 
hrs) but at a substantially lower cost. 
In this multicenter work, involving five different Italian laboratories, we evaluated the performance 
of RAPIDEC® CARBA NP in a proficiency test carried out by each laboratory with a collection of 
20 well-characterized carbapenem-resistant strains representative of different Gram-negative 
species and resistance mechanisms, and then in a field test with 50 clinical isolates from each 
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laboratory. 
Results revealed an overall high specificity of RAPIDEC® CARBA NP for detection of CP strains, 
similar to that previously reported by Poirel and Nordmann (2015) (96%), Garg et al. (2015) 
(96.2%) and Kabir et al. (2016) (98.5%). The false-positive results, observed with K. pneumoniae 
and P. aeruginosa isolates, and reported also by other Authors (Poirel and Nordmann, 2015; Lifshitz 
et al., 2016; Österblad et al., 2016), could be attributable to a reduced stability of the imipenem 
substrate used in the test toward strains producing enzymes that are not true carbapenemases but 
have some weak carbapenemase activity (e. g. AmpCs, CMY, CTX-M-type producers), and 
possibly also to the use of the inoculum recommended in the Manufacturer’s instructions. Indeed, 
Dortet et al. (2015) identified a critical impact of the bacterial inoculum in the performance of the 
test, and recommended the use of a much higher inoculum to avoid false positive results.   
On the other hand, the test frequently failed to detect A. baumannii complex strains producing class 
D β-lactamases, a problem reported also by other authors (Poirel and Nordmann, 2015; Kabir et al., 
2016) and probably due to the overall weak carbapenemase activity of class D carbapenemases 
(Queenan and Bush, 2007). A lower overall sensitivity (70%) was detected in this work compared 
to previously reported studies by Garg et al. (2015) (92.6%), Kabir et al. (2016) (97.8%), and Poirel 
and Nordmann (2015) (96%). This difference could be partially ascribed to the higher percentage of 
class D producing A. baumannii complex (12.5%) tested in our study (Garg et al. [2015] 0%, Kabir 
et al. [2016] 4.7%, and Poirel and Nordmann [2015] 8.5%). Also Noël et al. (2016) showed that 
RAPIDEC® CARBA NP performed poorly for the detection of class D carbapenemase-producing 
Acinetobacter spp. isolates (sensitivity 36.4%, specificity 75%), leading us to conclude that this test 
should not be used with A. baumannii complex isolates in its present format. A much higher 
bacterial inoculum, compared to the Manufacturer’s instructions, could increase the sensitivity of 
the tests (Lifshitz et al., 2016). Indeed, Dortet et al. (2015) recommended to perform the test using a 
standardized inoculum (a full 10 µl loop), which is critical for test reliability.  
A limitation of the prospective evaluation of RAPIDEC® CARBA NP carried out in this work is 
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represented by the relatively low number of isolates producing some types of carbapenemases (e. g. 
OXA-48 or VIM), and of carbapenemase-producing P. aeruginosa isolates, which reflected the 
local epidemiology of infections. 
Considering Enterobacteriaceae isolates only, the values of sensitivity and specificity were high 
and comparable with other works (Dortet et al., 2015; Hombach et al., 2015; Lifshitz et al., 2016), 
showing that RAPIDEC® CARBA NP test could be useful also for detecting CP Enterobacteriaceae 
from positive blood cultures processed with a fast-workflow approach. With this approach, 
RAPIDEC® CARBA NP can be used to reduce the time required for identification of CP 
Enterobacteriaceae to less than 9 hours since positivization of blood cultures (from at least 24 to 48 
hours of routine methods) (Morgenthaler and Kostrzewa, 2015). The rapid identification of CP 
Gram-negatives from blood cultures can be of remarkable importance to antimicrobial stewardship 
(Barlem et al., 2016). It should be noted, however, that the possibility of using a fast workflow is 
dependent on the laboratory schedule. For instance, in the laboratories participating in this work, 
which do not process positive blood cultures on a 24/7 schedule, the fast workflow could only be 
performed with blood cultures that were found to be positive or became positive in the morning. 
When the RAPIDEC® CARBA NP is used with positive blood cultures in the rapid workflow, 
another limitation could be represented by an insufficient bacterial growth for inoculum at 6 hours. 
However, in our experience this occurred only with a small number of cases (3 of 122, 2.4%). 
A limitation of the RAPIDEC® CARBA NP test is that it cannot discriminate the type of 
carbapenemase produced. This information is important for antimicrobial stewardship since the new 
antibiotics active against CP-GNB that are entering clinical practice (e. g ceftazidime-avibactam) 
may not cover all types of CP strains. In this perspective, the RAPIDEC® CARBA NP could have a 
role as a screening test for excluding carbapenemase production and selecting the most suitable 
candidates for characterization of the carbapenemase type by molecular platforms or 
immunoenzymatic assays (Banerjee et al., 2015; Raich and Powell, 2015; Meunier et al., 2016).  
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Figure 1. Workflow for the detection of carbapenemase producers in different clinical isolates. 
Significant pathogen indicates the presence of a suspect pathogen in a significant count (if 
applicable for the specimen type), present as a pure culture or as a mixed population with 
commensals derived from sampling the nonsterile site, considered to be clinically significant and 
subjected to further identification, AST and reporting.  
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Table 1 
Gram-negative strains selected for the evaluation of RAPIDEC® CARBA NP proficiency with the test results 
obtained in each site. 
Strain Species 
Principal Acquired  
β-lactamase 
 
Reference 
MIC 
Meropenem 
(µg/mL) 
 
RAPIDEC® results 
(center) 
Expected 1 2 3 4 5 
6-419 Escherichia coli No-one - 0.5 − − − − − − 
23-1786 Enterobacter ludwigii NMC-A 
Antonelli et 
al., 2015c 32 + + + + + + 
7-556 K. pneumoniae NDM-1 - 32 + + + + + + 
22-1706 E. coli NDM-5 - >32 + + + + + + 
7728 P. aeruginosa IMP-13 - 4 + + − +* + + 
ATCC 25922 E. coli no-one - 0.5 − − − − − − 
47-3752 E. cloacae complex IMI-2 - >32 + + + + +* + 
CVB-1 E. coli NDM-1 D’Andrea et al., 2011 32 + + + + + + 
ECBZ-1 E. coli OXA-48 Giani et al., 2012 1 + + + + +*
 + 
FIPP-1 K. pneumoniae KPC-3 Giani et al., 2009 >32 + + + + + + 
VA-417/02 E. cloacae complex VIM-4 
Luzzaro et 
al., 2004 32 + + + + + + 
FI-14/157 P. aeruginosa FIM-1 Pollini et al., 2013 >32 + + − + + + 
Cfr-FI-07 C. freundii OXA-372 Antonelli et al., 2015b 16 + + + + − + 
45A02 K. pneumoniae FOX-7 + porin deficiency Arena et al., 2013 4 − − − − − − 
NV132 A. baumannii complex OXA-58 - 8 + +* − + +* − 
8-27 K. pneumoniae CTX-M-1-like + OMP deficient - 2 − − − − − − 
10-52 K. pneumoniae CTX-M-1-like + OMP deficient - 2 − − − − − − 
VA-416/02 K. pneumoniae VIM-4 Luzzaro et al., 2004 32 + + + + + + 
GW1 P. aeruginosa GES-2 Poirel et al., 2001 16 − − − − − − 
PIEcl 
E. cloacae 
complex VIM-1  - >32 + + + + + + 
 
* Borderline positive: there was correctly a change of color in the test well, but it was not clear as described in manufacturer's instructions.  
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Table 2 
Primers and probes used in this study for three different multiplex Real Time PCR. 
Investigated 
bacteria Target Primer name Sequence (5’-3’) Reference Positive control 
Concentration 
of use in  
reaction mix 
(nM) 
En
ter
ob
ac
ter
iac
ea
e a
 
blaOXA-48-like  
genes 
OXA-48-like-rt-F GTAGCAAAGGAATGGCAAGAAA Antonelli et al., 2015a E. coli ECBZ-1 
(OXA-48) 
 (Giani et al., 
2012) 
500 
OXA-48-like-rt-R GATGCGGGTAAAAATGCTTG Antonelli et al., 2015a 500 
OXA-48-like-rt-P HEX-CTCTGGAATGAGAATAAGCAGCAAGG-BHQ-1 Antonelli et al., 2015a 125 
blaKPC  
 genes 
kpc-hind-fwd GATACCACGTTCCGTCTGG Hindiyeh et al., 2008 K. pneumoniae 
FIPP-1 (KPC-3) 
(Giani et al., 
2009) 
500 
kpc-hind-rev GCAGGTTCCGGTTTTGTCTC Hindiyeh et al., 2008 500 
kpc-hind-tq FAM-AGCGGCAGCAGTTTGTTGATTG-BHQ-1 Hindiyeh et al., 2008 125 
blaVIM  
genes b 
VIM-rt-fwd TGGTCTCATTGTCCGTGATG Antonelli et al.,  2016 K. pneumoniae  
VA-416/02 
 (VIM-4), 
(Luzzaro et al., 
2004) 
500 
VIM-rt-rev CATGAAAGTGCGTGGAGA Antonelli et al., 2016 500 
VIM-rt-tq ROX-AAGCAAATTGGACTTCCCGTAACGC-BHQ-2 
Antonelli et al., 
2016 
 125 
blaNDM  
genes 
blaNDM1_F CGCAACACAGCCTGACTTT Ong et al., 2008 E. coli CVB-1 
 (NDM-1) 
 (D’Andrea et al., 
2011) 
500 
blaNDM1_R TCGATCCCAACGGTGATATT Ong et al., 2008 500 
blaNDM1_P CY5-CAACTTTGGCCCGCTCAAGGTATTT-BHQ-3 Ong et al., 2008 125 
P.
 ae
ru
gin
os
a c
 
blaFIM-1  
gene 
FIM-rt-F CGCCTTAACACCCGTCGTGA This study P. aeruginosa FI-
14/157 (FIM-1) 
(Pollini et al., 
2013) 
500 
FIM-rt-R GTCTCCTTTTTCAACGATTAGCC This study 500 
FIM-rt-P HEX- CTGGCGTACAAGCGGCTCAACCCAA- BHQ-1 This study 125 
blaGES 
genes GES-rt-F AGAATTGACTCAGGCACCGAG This study 
P. aeruginosa 
GW1 (GES-2) 
(Poirel et al., 
2001) 
500 
 GES-rt-R GTTAGTAGCCCCATTGTCGC This study 500 
 GES-rt-P CY5- GAACCGTCATGTGTCCCGATGCTAG-BHQ-3 This study 
P. aeruginosa FI-
5/7728 (IMP-13), 
unpublished 
125 
blaIMP  
genes 
IMP-rt-F GANGCYTAYHTRATWGAYACTCCA This study 2000 
IMP-rt-R GRRATDGAYYGAGARTTAAGCCA This study 2000 
IMP-rt-P FAM- ATTCCNSCYGHRCTRTCRCYATGRAAATG- BHQ-1  This study 250 
A.
 ba
um
an
nii
 co
mp
lex
 c  
blaOXA-23-like  
genes oxa-23-like-rt-F GATTGTTCAAGGACATAATCAGGTG This study 
A. baumannii 
Ab13 (OXA-23) 
(Coverc et al., 
2007) 
500 
 oxa-23-like-rt-R GGTTCTCCAATCCGATCAGGG This study  500 
 oxa-23-like-rt-P FAM- AGGCTGGCACATATTCTGTATTTGCGG- BHQ-3 This study 125 
blaOXA-24-like  
genes oxa-24-like-rt-F CTTCCTATHYTCAGCATTTCTATTCTAG This study 
A. baumannii 
VA-566/00 
(OXA-40/24), 
(D’Andrea et al., 
2009) 
1000 
 oxa-24-like-rt-R 
ATCTTAAATGTTGAYGCAGGGAC This study 
1000 
 oxa-24-like-rt-P HEX- GCTATTTTGATGAAGCTCAAACACARGGT- BHQ-1 This study  250 
blaOXA-58-like  
genes 
oxa-58-like-rt-F AAAGCATGGGACAAAGATTTTAC This study A. baumannii 
NV132  
(OXA-58),  
unpublished 
500 
oxa-58-like-rt-R CAAACTTTACTTCTTGTATAGGTGT This study 500 
oxa-58-like-rt-P ROX- CAGTGCCTGTATATCAAGAATTGGCAC- BHQ-2 This study 125 
ISAba1+ 
blaOXA-51-like  
genes  
ISABA1-oxa-51-rt-F ATAATCACAAGCATGATGAGCG This study A. baumannii 
696/03  
(OXA-58),  
unpublished 
500 
ISABA1-oxa-51-rt-R GTGARCAGGCTGAAATARRAATAG This study 500 
ISABA1-oxa-51-rt-P CY5- ATGAACATTAAAGCACTCTTACTTATAACAAG- BHQ-3 This study 125 
Ev
ery
on
e PhHV  
(internal 
 control) 
PhHV-267s GGG CGA ATC ACA GAT TGA ATC Van Doornum et al., 2003 PhHV DNA 
cloned in pGEM-
T-easy E. coli 
DH5α 
500 
PhHV-337as GCG GTT CCA AAC GTA CCA A Van Doornum et al., 2003 500 
PhHV-305tq Cy5.5 -TTTTATGTGTCCGCCACCATCTGGATC-BHQ-3 Van Doornum et al., 2003 125 
aThe amplification program consisted of 35 two-step cycles of 15 s at 95°C and 60 s at 60°C. 
bblaVIM genes were also target of the multiplex Real Time PCR used for P. aeruginosa isolates. 
cThe amplification program consisted of 35 three-step cycles of 15 s at 95°C, 30 s at 50°C and 30 s at 60°C. 
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Table 3 
Comparison of the results obtained from RAPIDEC® CARBA NP test with the 
molecular detection of carbapenemase genes. Discrepant RAPIDEC® CARBA NP 
results are underlined. 
 
Origin of 
Isolates Species 
No. of 
isolates 
MIC MEM 
(µg/ml) Carbapenemase genes 
RAPIDEC®  
Result 
va
rio
us
 m
ate
ria
ls 
 
Enterobacteriaceae 
 
10 16 to >128 blaKPC + 
1 32 blaOXA-48-like + 
1 16 blaKPC+blaVIM + 
48 ≤0.03 to 4 No one − 
1 0.25 No one + 
P. aeruginosa 
4 16 to >128 No one + 
35 ≤0.03 to 64 No one − 
    1 2 No one + 
A. baumannii 
complex 
7 64 to >128 blaOXA-23-like + 
9 8 to 128 blaOXA-23-like − 
1 64 blaOXA-24-like + 
1 2 blaOXA-24-like − 
1 2 ISAba1+blaOXA-51-like − 
5 0.25 to 8 No one − 
blo
od
 cu
ltu
res
  
Enterobacteriaceae 
18 8 to >128 blaKPC  + 
2 1 to 4 blaOXA-48-like + 
1 4 blaVIM  + 
59 ≤0.03 to 2 No one − 
1 ≤0.03 No one + 
1 ≤0.03 No one a 
P. aeruginosa 
3 8 to >128 blaVIM  + 
1 >128 blaVIM  a 
1 >128 No one + 
20 0.12 to >128 No one − 
2 0.12; 0.5 No one + 
A. baumannii 
complex 
1 128 blaOXA-23-like and  blaOXA-24-like − 
7 16 to >128 blaOXA-23-like − 
3 16 to 64 blaOXA-23-like + 
1 >128 blaOXA-24-like − 
1 >128 blaOXA-23-like a 
3 0.25 No one − 
a insufficient biomass 6 hours after subculture.  
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Table 4  
Performance of RAPIDEC® CARBA NP test with clinical isolates. 
Sources 
 Species/Family 
Se
ns
iti
vit
y %
 
Sp
ec
ifi
cit
y %
 
PP
V%
 
NP
V%
 
 
All 
     
All (N=247) 70 94 82 89 
Excluding A. baumannii complex 
(N=208) 100 94 78 100 
Enterobacteriaceae (N=142) 100 98 94 100 
Blood 
cultures 
All (N=122) 75 95 87 90 
Excluding A. baumannii complex 
(N=107) 
100 95 86 100 
Enterobacteriaceae (N=81) 100 98 95 100 
Other 
materials 
All (N=125) 65 94 77 89 
Excluding A. baumannii complex 
(N=101) 
100 93 67 100 
 Enterobacteriaceae (N=61) 100 98 92 100 
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Highlights 
• RAPIDEC® CARBA NP could detect carbapenemase producers from positive blood 
cultures, after 6 hours of subculture 
• The test showed low sensitivity with carbapenemase-producing A. baumannii 
• Excluding A. baumannii the test showed high sensitivity (100%) and specificity 
(94%) 
 
